Improving the management of ALK-rearranged non-small-cell lung cancer through a mobile application: a physicians-based survey

Pharmacogenomics. 2023 Aug;24(13):725-730. doi: 10.2217/pgs-2023-0111. Epub 2023 Sep 14.

Abstract

Background: ALK rearrangements account for around 5% of non-small-cell lung cancers. Aim: This study surveys physicians on the potential efficacy of a mobile application in improving the management of ALK-rearranged non-small-cell lung cancer, through knowledge, treatment adherence and real-time adverse events reporting. Materials & methods: A total of 118 physicians from 11 countries in the Middle East participated. Results & conclusion: Results indicate 94% support for enhancing team communication via an application, and 93% believe real-time adverse events reporting improves the quality of care. Participants found an ALK-rearrangement patient-physicians forum valuable for communication improvement. Motivations for application use included treatment planning (73%), care enhancement (60%) and contributing to publications (40%).

MeSH terms

  • Anaplastic Lymphoma Kinase / genetics
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Gene Rearrangement
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Physicians*
  • Protein Kinase Inhibitors / adverse effects
  • Receptor Protein-Tyrosine Kinases / genetics

Substances

  • Receptor Protein-Tyrosine Kinases
  • Anaplastic Lymphoma Kinase
  • Protein Kinase Inhibitors